Peer-Reviewed Publication
BMJ Open2025;15(5):e098030.May 21, 2025Journal Article
Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER): design and rationale for a decentralised, real-world cluster-randomised controlled trial and implementation study.
Mihir A Kelshiker1,2, Patrik Bächtiger1,2, Josephine Mansell1,2, Daniel B Kramer1,3, Saloni Nakhare1,2, Melanie T Almonte1,2, Abdullah Alrumayh1, Camille F Petri1, Alexei Peters1, Ceire Costelloe4, Emanuela Falaschetti5, Carys Barton2, Rasha Al-Lamee1,2, Azeem Majeed4, Carla M Plymen2, Nicholas S Peters6,2
1National Heart and Lung Institute, Imperial College London, London, England, UK.
2Imperial College Healthcare NHS Trust, London, England, UK.
3Harvard Medical School, Boston, Massachusetts, USA.
4School of Public Health, Imperial College London, London, UK.
5Imperial Clinical Trials Unit, Imperial College London, London, England.
6National Heart and Lung Institute, Imperial College London, London, England, UK n.peters@imperial.ac.uk.
Abstract
INTRODUCTION: Early detection of cardiovascular disease in primary care is a public health priority, for which the clinical and cost-effectiveness of an artificial intelligence-enabled stethoscope that detects left ventricular systolic dysfunction, atrial fibrillation and cardiac murmurs is unproven but potentially transformative.
METHODS AND ANALYSIS: TRICORDER is a pragmatic, two-arm, multi-cen…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans